"Paralyzing Uncertainty" Does Not Create Declaratory Judgment Jurisdiction
Client Alert | 2 min read | 09.04.08
In Prasco, LLC v. Medicis Pharmaceutical Corporation and Imaginative Research Associates, Inc. (No. 07-1524; August 15, 2008), the Federal Circuit further clarifies the scope of declaratory judgment jurisdiction in patent cases. The Federal Circuit explains that although the Supreme Court found that an actual controversy can exist when there is no apprehension of suit in MedImmune Inc. v. Genentech, Inc., 127 S. Ct. 764 (2007), "it did not change the bedrock rule that a case or controversy must be based on a real and immediate threat of future injury that is caused by defendants - an objective standard that cannot be met by a purely subjective or speculative fear of future harm."
Prasco filed for a declaratory judgment that its benzoyl peroxide cleansing product did not infringe four patents listed on Medicis' competing benzoyl peroxide product. Prasco claimed that although it had not yet begun marketing its product, it had devoted substantial efforts to development and marketing plans and that it suffered "paralyzing uncertainty" from fear that Medicis would sue for patent infringement.
In affirming the district court's dismissal, the Federal Circuit finds Prasco's paralyzing uncertainty argument insufficient, noting that a patentee's marking of its products with applicable patent numbers provides little, if any, evidence that the patentee will ever enforce its patents. Thus, patent marking is irrelevant to the question of an imminent threat of harm sufficient to create an actual controversy. The Court also indicates that although failure to sign a covenant not to sue is a circumstance to be considered, it is not sufficient on its own to create an actual controversy. The Court explains that some affirmative action by patentee is usually necessary to create such a controversy and that a patentee has no obligation to spend the time and money to test a competitor's product nor to make a definitive determination, at a competitor's request, that it will never bring an infringement suit. In fact, where a competitor does approach a patentee with such a request, the patentee's silence does not alone make an infringement action or other interference with the competitor's business imminent and does not confer declaratory judgment jurisdiction.
Contacts
Insights
Client Alert | 4 min read | 08.29.25
Gender-Affirming Care Targeted for Potential False Claims Act Enforcement
On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments.
Client Alert | 4 min read | 08.28.25
9th Circuit Marches Forward to the Future Finding Digital Assets Are Protected Under Trademark Law
Client Alert | 2 min read | 08.27.25
CPSC Maintains Momentum on eFiling Requirements for Consumer Products
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions